Recombinant retroviruses are one of the most commonly used gene transfer vehicles for therapeutic gene delivery. The stability of viral vectors upon long-term storage, anticipated to be short lived, is expected to impact timeline and financial course of clinical immunogene therapy. However, to date little is known about vector stability. Therefore, we analyzed the stability of retroviral vectors produced in culture supernatants (RTVsup) for ex vivo gene therapy upon long-term storage. We have generated RTVsups derived from two packaging cell lines, PG13 and Phoenix(Ampho). Both lines produced murine leukemia virus-derived SFG-scFv(G250)-CD4g vector, which were pseudotyped with the gibbon ape leukemia virus envelope and amphotropic envelope, respectively. The supernatants were stored at À80 or À196 1C. To date, the PG13-derived RTVsups have been evaluated over a period of 9 years (1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007). In addition, a clinical batch of Phoenix(Ampho)-derived RTVsup has been evaluated over a period of 5 years (2002)(2003)(2004)(2005)(2006)(2007). Here, we show that both RTVsups, when stored up to 9 and 5 years, respectively, do not show any sign of decay in their capacity to functionally transduce primary human T cells. These data provide evidence that in terms of 'life expectancy' the production and storage of clinical batches of RTVsup for gene therapy warrants the corresponding professional and financial risks.
Introduction
Retroviral vectors are the most commonly used vectors for ex vivo gene therapy. 1, 2 We have described procedures for the production of high-titer clinical-grade retroviruscontaining culture supernatant (RTVsup) and clinicalscale retroviral transduction that yield clinically relevant numbers of stably transduced human T cells for patient treatment. 3 However, it has been recognized that retroviral vectors, in particular murine leukemia virus (MLV)-derived vectors furnished with an amphotropic envelope, are relatively labile. 4, 5 Among the factors that influence retroviral vector stability are physicochemical properties of the viral lipid shell such as the cholesterol:phospholipid ratio. This property is dictated by the host cell and the virus production conditions, including temperature, 6, 7 osmotic pressure and producer cell line metabolism. [8] [9] [10] In addition, downstream processing, formulation and storage temperature further determine the half-life of retroviral vectors. As a result, the variation in reported vector half-lives, which is generally represented by infectious titers, can be significant and range from 2 to 9 h, 8 to 300 h and 19 days to 18 months when stored at 37, 4 and À80 1C, respectively. [4] [5] [6] [7] [11] [12] [13] A limited half-life of retroviral vectors would be a major concern to the planning and costs of clinical immunogene therapy. Good manufacturing practice (GMP) production of the vector, followed by safety and potency testing and the subsequent release for clinical application take at least 6-12 months (Lamers et al., data not shown). In addition, obtaining approval of the clinical gene therapy protocol by the national and local regulatory authorities may take an additional 6-30 months.
We have developed an immunogene therapeutic strategy against metastatic renal cell cancer (RCC) using adoptive transfer of autologous T cells that have been gene transduced to express a single-chain G250 antibody chimeric receptor (scFv(G250)). 14 To this end, we have constructed two stable packaging cell lines that produce a SFG-scFv(G250)-CD4g retrovirus. 15, 16 In the current paper, we have performed a long-term functional potency (that is, stability) study of RTVsup. RTVsups derived from the virus-producing PG13 clone 1.2, 15 containing the gibbon ape leukemia virus (GaLV)-enveloped SFG-scFv(G250)-CD4g retrovirus were tested for their functional transduction capacity on primary human T lymphocytes over a period of 9 years (1998-2007) . Phoenix(Ampho)-derived SFG-scFv(G250)-CD4g retrovirus, containing the MLV envelope, showed improved functional transduction efficiency when compared with PG13-derived retrovirus 16 and was selected for our clinical immunogene therapy study.
14 A clinical lot of RTVsup was produced using the stable virus-producing packaging cell line Phoenix(Ampho) clone 58. 16 The functional transduction capacity of this clinical batch of RTVsup was tested over a period of 5 years (2002-2007) . Our retroviral vector lacks a selectable marker and when our study started (1998), no quantitative PCR method was available to quantify numbers of infectious vector particles. Therefore, we have chosen to use a surrogate marker for vector stability, that is the potency to functionally transduce our target cell population (primary human T cells).
Materials and methods
Cells, media and antibodies Sodium heparin anti-coagulated blood was collected from healthy volunteers after written informed consent was obtained. Peripheral blood mononuclear cells (PBMC) were isolated as described 15 and cryopreserved and stored at À196 1C in liquid nitrogen (N 2 ) until use. Cell lines were cultured in Dulbecco's modified Eagle's medium or RPMI-1640 medium containing 10% fetal calf serum (FCS, Summit Biotechnology, FtCollins, CO, USA), 2 mM L-glutamin, 1% MEM-NEAA and 1% penicillin/ streptomycin. Media and supplements were purchased from Lonza (formally Cambrex/Bio-Whittaker, Verviers, Belgium). Target cell lines used for cytotoxicity assays were the CAIX þ RCC cell line SKRC-17 MW1-clone 4 and the CAIX À RCC cell line SKRC-17 PBJ-clone 1. G250 monoclonal antibody (mAb) was a gift from Dr S Warnaar (Wilex AG, Munich, Germany), and the G250 anti-idiotype mAb NUH-82 (IgG 1 ) from Dr E Oosterwijk (Nijmegen, The Netherlands). Goat anti-mouse IgG 1 (GAM) conjugated to phycoerythrin (PE) was purchased from Southern Biotechnology (Birmingham, AL, USA).
Retroviral supernatant
The stably transduced PG13 clone 1.2 15 was used to produce the GaLV-enveloped SFG-scFv(G250)-CD4g RTVsup as described. 15 Two production media were used, that is, RPMI-1640 supplemented with 2% human serum albumin ( Retroviral transduction of primary human T lymphocytes PBMC were activated as described, 3 followed by two cycles of transduction at days 2 and 3 postactivation. Over a period of B10 years our (laboratory-scale) transduction protocols have been significantly optimized. The initial T-lymphocyte transduction protocol (Protocol I, 1998), using polybrene (final concentration 8 mg ml
À1
; Sigma, St Louis, MO, USA), 15 was replaced by a 'static' transduction protocol using recombinant fibronectin fragments CH-296 (final concentration 6 mg cm À2 , Retronectin, Takara, Otsu, Japan) 15 (Protocol II, 1999), which was subsequently further improved by including centrifugation steps (Protocol III, 2001). 3, 16 From day 4 postactivation onwards, the transduced T cells were expanded until day 14 as described. 3 
Flow cytometry
Transduced T lymphocytes were analyzed at days 7, 11 and 14 postactivation (which is 3, 7 and 11 days after transduction) for surface membrane expression of the scFv(G250)-CD4g receptor by indirect immunofluorescence using the G250 anti-idiotype mAb NUH-82, 17 followed by GAM IgG 1 /PE, as described. 15 Cytotoxicity assay Transduced T lymphocytes were analyzed at day 14 postactivation (which is 11 days after transduction) for scFv(G250)-CD4g receptor-mediated cytolitic activity in a standard 4 h 51 Cr-release assay using the CAIX þ RCC cell line SKRC-17 MW1-clone 4 as target cell. 15 In experiments aimed at specific blocking of CAIX-specific lytic activity, G250 mAb (25 mg ml À1 final concentration) was added to the targets cells 15 min before addition of the effector T cells. The percentage of specific cytolysis was expressed as weighted mean of specific lysis (WMSL) at effector target ratio of 10:1, as described. 16 
Results

Transduction efficiencies of different types of PG13-derived RTVsup as function of transduction protocol
Two batches of PG13 clone 1.2 RTVsup in RPMI-1640 medium supplemented with either 2% HSA or 10% FCS were produced in February 1998, aliquoted and stored at À80 1C as well as at À196 1C in liquid nitrogen. For the PG13-derived RTVsup, transduction protocols have been improved in time, making it impossible to take transduction efficiency at the first month after production as standard. Therefore, we have chosen to use transduction efficiency by RTVsup stored at À196 1C as an internal standard, since storage at this temperature is expected to best preserve retroviral vector integrity and stability over time. To investigate the stability of retroviral vectors stored at À80 1C we compared the transduction potency of these RTVsups with those stored at À196 1C at regular intervals from their production date, which is currently nearly a decade ago.
Over time, transduction protocols have improved considerably. We have dealt with this time-dependent parameter by classifying transduction protocols as follows; protocol I, polybrene-mediated transduction (period 1998); protocol II, Retronectin-mediated transduction (no centrifugation, period 1999-2000) and protocol III, Retronectin-mediated transduction including centrifugation steps (period 2001-2007) . As illustrated in Figure 1 (upper row of panels), transduction efficiencies are expressed as %scFv (G250) þ T cells and using protocol I (polybrene) ranged from 10 to 18%, with no apparent differences between the different RTVsups. Transduction efficiencies according to protocol II (Retronectin, no centrifugation) ranged from 24 to 51% with significant higher transduction efficiencies for FCS-supplemented Functional stability of PG13-derived RTVsup upon long-term storage at À80 1C In Figure 2 , kinetics of transduction potencies of our RTVsups, supplemented with HSA or FCS and either stored at À80 or À196 1C, are graphically presented in relation to transduction protocol III. Despite observed fluctuations in absolute levels of transduction efficiency between experiments, the performance of the different RTVsups was virtually constant. The observed fluctuations are due to minor experimental variation (for example, fluctuations of incubator temperature) rather than donor variation (data not shown). For a proper comparison over time and independent of transduction protocol, we expressed transduction efficiencies and proportions of specific cytolysis of T cells corresponding to HSA-and FCS-containing RTVsups stored at À80 1C relative to those stored at À196 1C. Figure 3 (upper left panel) shows that the transduction efficiencies obtained by both HSA-and FCS-supplemented RTVsups stored at À80 1C were identical to those stored at À196 1C, irrespective of the transduction protocol used over an observation period of 9 years. In addition, HSAsupplemented RTVsups performed less than the FCSsupplemented RTVsups in the Retronectin-mediated transductions (protocols II and III), at about 80% with FCS conditions set at 100% (Figure 3, upper right panel) . The observed superiority for FCS-containing RTVsups upon transductions using protocol III is stable over time and independent of storage temperature. Although relative proportions of specific cytolysis are more variable, probably due to bioassay variability, they do show stability over time for both supplements and storage temperatures ( Figure 3 , lower left panel). However, observed differences in transduction efficiencies between HSA-and FCS-supplemented RTVsups ( Figure 3 , upper right panel) do not translate into differences at the levels of specific cytolysis ( Figure 3 , lower right panel).
Stable transduction potency of clinical batch of Phoenix clone 58 RTVsup
Next, we tested the stability of the clinical lot of Phoenix clone 58 Retroviral supernatant stored at À80 1C at regular intervals (to date, up to 5 years since production) using identical batches of cryopreserved PBMC derived from five healthy donors. Tests were performed according to our standardized protocol and using clinical-grade components, 3 and resulted in highly reproducible transduction efficiencies, with very limited inter-donor and inter-test variations (Figure 4 ). Only donor 5 performed slightly less than the other donors (all t-tests Pp0.02) (Figure 4, left panel) . At the first assay time point, at 1 month since production, the transduction efficiency of the clinical-batch RTVsup was 83% (median, range 72-85%). This result was stable over time. None of the results obtained at the subsequent seven time points following production deviated significantly from this first observation, except for those obtained at 34 months (Figure 4 , right panel). At 34 months following production transduction efficiencies were slightly elevated when compared to the results at 7, 14 and 57 months following virus production (all t-tests Pp0.01). Again, the relative proportions of specific cytolysis showed consistency over time, and variation found could be attributed to inter-test variability (data not shown).
Discussion
In the present study, we demonstrate that the MLVderived retroviral vector SFG-scFv(G250)-CD4g pseudotyped either with an amphothropic or GaLV envelope is stable for at least 9 years when stored as culture supernatant in a controlled freezer at À80 1C. To date, the different batches of retroviral culture supernatant do not show a compromised capacity to transduce primary human T cells. From the start of our experiments in 1998 we have chosen to assess the transduction potency of the vector supernatants on primary human T cells using optimized clinical-scale protocols. We choose transduction efficiency to be a surrogate marker for vector stability for the following reasons: (1) our retroviral vector lacks a selection marker, which would facilitated other/nonfunctional quantification methods; [18] [19] [20] (2) PCR-based methods would have been unable to discriminate defective virus particles or detect the presence of inhibitors of transduction 21, 22 and (3) infection of compatible cell lines such as 293 and Mus Dunni for GaLV-and MLV-pseudotyped vectors, respectively, demonstrate considerable biovariability (data not shown).
These data are of special interest, as they indicate that at least in terms of 'life expectancy' of clinical batches of RTVsups professional and financial risks of embarking on ex vivo retroviral gene therapy may be warranted and are more limited than previously assumed. Our data provide evidence that an ex vivo retroviral gene therapy trial may pass all its phases (approval, start and completion) with no loss of activity of appropriately supplemented and stored clinical batches of RTVsup.
In 1998, we aimed at a clinical protocol using polybrene-mediated T-cell transductions and using a bovine serum-free, HSA-supplemented RTVsup. Indeed, HSA-supplemented RTVsup performed as good as FCSsupplemented RTVsup in polybrene-mediated transductions. However, FCS-supplemented RTVsup appeared to be superior in Retronectin-mediated transductions. As HSA-supplemented RTVsup stored at À80 and À196 1C performed similarly well, the lower transduction efficiencies of HSA vs FCS-supplemented RTVsups are probably due to differences in vector titer rather than decay of the HSA-supplemented RTVsup by long-term storage. When batches of clinical-grade FCS became available, we further used the latter reagent because of its superior performance to supplement the RTV production medium and used FCS-supplemented RTV production medium to generate our clinical lot of RTVsup. 3 Optimization of conditions to produce and preserve stability of retroviral vectors is crucial for clinical gene therapy applications. First, the choice of the producer cell line is of utmost importance to obtain a high-level producer cell line. 23 Next, the virus production conditions should be considered, not only to generate a high-titer vector culture supernatant, but also to enhance its infectivity and maintain vector stability. [6] [7] [8] [9] [10] Many retrovirus production protocols, including ours, 3, 15, 16 produce virus at 32 1C, which is based on the observation that 5-to 10-fold higher vector titers are obtained at 32 1C when compared to 37 1C. This is not due to a higher production rate, but to a fourfold increased half-life of the vectors at 32 1C when compared to 37 1C.
11 Despite this advantage, recent studies also revealed significant drawbacks of virus production at 32 1C, such as the adverse effect of the production temperature on the viral lipid shell constitution. Decreasing the production temperature from 37 to 32 1C increases the level of cholesterol in the viral membrane, 6 while viral thermal stability at ambient temperature and 4 1C is inversely correlated with the cholesterol content in the viral membrane. 6, 7 Moreover, the cholesterol content enhances the viral membrane rigidity, which negatively affects infectivity of human immunodeficiency virus 24, 25 and amphotropic MVL. 26 To improve vector quality, production methods are being designed to optimize cholesterol content in viral membranes, 27 and thereby improving vector stability. Retroviral vector characteristics may be manipulated through specific changes in the production temperature and medium composition (for example, with decreased cholesterol concentrations or cholesterol inhibitors).
Thus far, data on stability of retroviral vectors stored at À80 1C are limited. Wikstro¨m et al. 13 reported a retroviral vector half-life of about 18 months during storage at À80 1C. However, this conclusion may not hold true as the internal control 'decayed' at the same rate as their test samples. Carno et al. 7 determined a half-life of 11 and 17 days for amphotropic MLV virus that had been produced at 32 and 37 1C, respectively, followed by storage at À85 1C. The tests by Carno et al. were performed with purified retroviral particles, and as mouse retroviruses are not only sensitive to storage temperature, but also to shear forces, pH and absorptive processes, 6 these data are not representative for the stability of 'nonmanipulated' retrovirus in culture supernatant and stored at À80 1C, which is common practice for clinical RTVsups. Furthermore, a half-life of 340 days was obtained in an attempt to stabilize retroviral vectors through lyophilization followed by storage at À20 1C.
28
For future in vivo gene therapy applications of retroviral vectors, one may consider to concentrate and purify vector preparations. The generation of clinical batches of stable 'purified' retrovirus upon long-term storage is still a biotechnological challenge. On the contrary, clinical-grade high-titer retroviral culture supernatants are produced at a 'routine basis' for current ex vivo gene therapy applications. Despite the fact that these production conditions may not be optimal for maximum viral infectivity and maintenance of stability, our nonpurified retroviral vector culture supernatants showed excellent long-term stability following storage at À80 1C.
